Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study

Table 2 Changes in anxiety and depression over time (n = 126), mean ± SD/n (%)

Time point	Patients assessed	HADS-A score	Anxiety ≥ 8	HADS-D score	Depression ≥ 8
Baseline	126	9.8 ± 4.2	74 (58.7)	10.3 ± 3.9	77 (61.1)
3 months	126	7.1 ± 3.8a	54 (42.9)	7.3 ± 3.5a	57 (45.2)
6 months	119	5.9 ± 3.2a	42 (35.3)	6.1 ± 3.0a	39 (32.8)
12 months	97	5.2 ± 2.9a	30 (30.9)	5.4 ± 2.7a	28 (28.9)
P value1	-	< 0.001	< 0.001	< 0.001	< 0.001

^aP < 0.001 vs baseline (post-hoc analysis with Bonferroni correction).

¹P value from repeated-measures ANOVA for overall time effect.

HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: Hospital Anxiety and Depression Scale-Depression subscale.